Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole

Investigational New Drugs, 05/10/2012

The results indicate that eribulin mesylate can be safely co–administered with ketoconazole. Drug–drug interactions are not expected with other CYP3A4 inhibitors.

Print Article Summary Cat 2 CME Report